Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Apellis Pharmaceuticals stock

Learn how to easily invest in Apellis Pharmaceuticals stock.

Apellis Pharmaceuticals Inc is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 486 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Apellis Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APLS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Apellis Pharmaceuticals stock price (NASDAQ: APLS)

Use our graph to track the performance of APLS stocks over time.

Apellis Pharmaceuticals shares at a glance

Information last updated 2022-01-24.
Latest market close$39.67
52-week range$27.50 - $73.00
50-day moving average $43.60
200-day moving average $48.73
Wall St. target price$70.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.47

Buy Apellis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Apellis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Apellis Pharmaceuticals price performance over time

Historical closes compared with the close of $39.67 from 2022-01-25

1 week (2022-01-19) 5.09%
1 month (2021-12-23) -19.30%
3 months (2021-10-22) 26.46%
6 months (2021-07-26) -40.58%
1 year (2021-01-26) -11.63%
2 years (2020-01-24) -3.95%
3 years (2019-01-25) 190.62%
5 years (2017-01-22) N/A

Apellis Pharmaceuticals financials

Revenue TTM $256.3 million
Gross profit TTM $-74,325,000
Return on assets TTM -30.6%
Return on equity TTM -2144.31%
Profit margin -202.97%
Book value $0.64
Market capitalisation $3.5 billion

TTM: trailing 12 months

Apellis Pharmaceuticals share dividends

We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.

Apellis Pharmaceuticals share price volatility

Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $27.5 up to $73. A popular way to gauge a stock's volatility is its "beta".

APLS.US volatility(beta: 1.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.5646. This would suggest that Apellis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Apellis Pharmaceuticals overview

Apellis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Frequently asked questions

What percentage of Apellis Pharmaceuticals is owned by insiders or institutions?
Currently 16.871% of Apellis Pharmaceuticals shares are held by insiders and 72.816% by institutions.
How many people work for Apellis Pharmaceuticals?
Latest data suggests 486 work at Apellis Pharmaceuticals.
When does the fiscal year end for Apellis Pharmaceuticals?
Apellis Pharmaceuticals's fiscal year ends in December.
Where is Apellis Pharmaceuticals based?
Apellis Pharmaceuticals's address is: 100 Fifth Avenue, Waltham, MA, United States, 02451
What is Apellis Pharmaceuticals's ISIN number?
Apellis Pharmaceuticals's international securities identification number is: US03753U1060
What is Apellis Pharmaceuticals's CUSIP number?
Apellis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 03753U106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site